Cipla stock faces DRI search at Mumbai office and depot
Published on 11/17/2026 at 03:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory search draws market attention
- India's Directorate of Revenue Intelligence searched Cipla facilities in Mumbai and Bhiwandi on November 16.
- Cipla said the proceedings would have no material impact on its finances, operations or other activities.
- The company operates across India, South Africa, the United States and other emerging markets.
Cipla said on Monday, November 16, that the Directorate of Revenue Intelligence searched its office in Vikhroli, Mumbai, and its depot in Bhiwandi, Thane, over the classification and exemption of an imported finished pharmaceutical product. The search was initiated and concluded that day under Section 105 of the Customs Act, 1962.
In a report by CNBC TV18, Cipla said it cooperated fully with the authorities. The drugmaker added that the proceedings would have no material impact on its financials, operations or other activities.
Recent earnings add context
The regulatory disclosure follows Cipla's second-quarter results. Revenue fell 2.4 percent year over year to INR 74.04 billion, while net income declined 35 percent to INR 8.78 billion, according to the same report. EBITDA decreased 26.7 percent to INR 13.88 billion, and the EBITDA margin narrowed to 18.7 percent from 25 percent a year earlier.
Cipla's One-India business delivered its highest quarterly sales, increasing 12 percent year over year. North American revenue was USD 172 million, while the Emerging Markets and Europe business generated USD 101 million during the quarter.
Global medicines portfolio
Cipla develops and supplies affordable medicines across therapeutic categories, with more than 1,500 products in over 50 markets and more than 30,000 employees. Its main geographic focus includes India, South Africa, the United States and other emerging economies. The company is headquartered in Mumbai and is listed on BSE Limited and the National Stock Exchange of India.
Cipla's broad portfolio spans tablets, capsules, respiratory products, injections, nasal sprays and other dosage forms. Its business combines branded and generic medicines with manufacturing and research activities serving healthcare providers and patients across multiple regions.
Cipla at a glance
- Company: Cipla Limited
- ISIN: INE059A01026
- Ticker: CIPLA
- Home exchanges: BSE Limited and National Stock Exchange of India
- Headquarters: Mumbai, India
- Business: Global pharmaceuticals
India's pharmaceutical sector remains the relevant market environment for Cipla, alongside the BSE Sensex.
More news and analyses on Cipla stock are available here.
